TREATMENT OUTCOMES OF NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTER (MGMT) STATUS: A MULTI-COUNTRY STUDY

被引：0
|
作者：
Fu, A. Z. [1 ,2 ]
Hall, J. P. [3 ]
Bailey, A. [3 ]
Kemp, J. [3 ]
Thompson, G. J. [4 ]
Lee, C. [1 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA
[3] Adelphi Real World, Manchester, Lancs, England
[4] Bristol Myers Squibb, Uxbridge, Middx, England
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
10.1093/neuonc/noz126.265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P14.30
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [1] TREATMENT PATTERNS BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTER (MGMT) STATUS IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A MULTI-COUNTRY CHART REVIEW STUDY
    Fu, A. Z.
    Thompson, G. J.
    Hall, J. P.
    Bailey, A.
    Kemp, J.
    Lee, C.
    NEURO-ONCOLOGY, 2019, 21 : 75 - 75
  • [2] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN US PATIENTS NEWLY DIAGNOSED WITH GLIOBLASTOMA MULTIFORME (GBM) BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTOR (MGMT) STATUS
    Fu, A.
    Gogate, A.
    Hall, J.
    Bailey, A.
    Massey, L.
    Marshall, A.
    VALUE IN HEALTH, 2020, 23 : S85 - S85
  • [3] Methylation status of MGMT (O6-methylguanine DNA methyltransferase) promoter in high-grade gliomas
    Choe, G. -Y.
    Moon, S. -Y.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 236 - 236
  • [4] Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
    Hegi, Monika E.
    Liu, Lili
    Herman, James G.
    Stupp, Roger
    Wick, Wolfgang
    Weller, Michael
    Mehta, Minesh P.
    Gilbert, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4189 - 4199
  • [5] O6-methylguanine-DNA-methyltransferase (MGMT) expression in patients with glioblastoma multiforme
    Jimenez, Daniel
    Manuel Matamala, Jose
    Chiti, Alessandra
    Vergara, Carmen
    Tissera, Claudia
    Melo, Romulo
    Cartier, Luis
    REVISTA MEDICA DE CHILE, 2018, 146 (01) : 7 - 14
  • [6] Immunohistochemical evaluation of O6-methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma
    Miyazaki, Masaya
    Nishihara, Hiroshi
    Terasaka, Shunsuke
    Kobayashi, Hiroyuki
    Yamaguchi, Shigeru
    Ito, Tamio
    Kamoshima, Yuuta
    Fujimoto, Shin
    Kaneko, Sadao
    Katoh, Masahito
    Ishii, Nobuaki
    Mohri, Hiromi
    Tanino, Mishie
    Kimura, Taichi
    Tanaka, Shinya
    NEUROPATHOLOGY, 2014, 34 (03) : 268 - 276
  • [7] A study of clinico-pathological parameters and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma
    Singh, Geetika
    Mallick, Supriyo
    Sharma, Vikas
    Joshi, Nikhil
    Purkait, Suvendu
    Jha, Prerana
    Sharma, Mehar Chand
    Suri, Vaishali
    Julka, Pramod Kumar
    Mahapatra, Ashok Kumar
    Singh, Manmohan
    Kale, Shashank Sharad
    Sarkar, Chitra
    NEUROPATHOLOGY, 2012, 32 (05) : 534 - 542
  • [8] THE CLINICAL SIGNIFICANCE OF TELOMERASE REVERSE TRANSCRIPTASE (TERT) PROMOTER MUTATIONS, TELOMERE LENGTH AND O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS IN NEWLY DIAGNOSED AND RECURRENT IDHWILDTYPE GLIOBLASTOMA (GBM) PATIENTS (PTS): A LARGE MONO-INSTITUTIONAL STUDY.
    Lombardi, G.
    Giunco, S.
    Cavallin, F.
    Angelini, C.
    Caccese, M.
    Cerretti, G.
    De Bonis, P.
    De Rossi, A.
    Zagonel, V.
    NEURO-ONCOLOGY, 2021, 23 : 1 - 2
  • [9] GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS: TREATMENTS, O-6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) METHYLATION STATUS AND SURVIVAL
    Abhinav, K.
    Aquilina, K.
    Gbejuade, H.
    La, M.
    Hopkins, K.
    Iyer, V.
    NEURO-ONCOLOGY, 2010, 12 : 10 - 10
  • [10] O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND THE INCIDENCE OF TEMOZOLOMIDE-INDUCED HEMATOLOGIC TOXICITY: AN ASSOCIATION STUDY
    Strohbusch, Alyssa
    Pound, Heather
    Regis, Patrick
    Cavaliere, Robert
    NEURO-ONCOLOGY, 2020, 22 : 135 - 135
12345